In the treatment of patients with type 2 diabetes and established CV disease receiving standard of care, CV death can strike at any time.

**BATTLE CV DEATH NOW MORE THAN EVER**

JARDIANCE demonstrated 38% RRR in CV death1,2

Established HbA1c efficacy3

Demonstrated safety profile3,4

Convenient, once-daily oral dosing3

**ADA & EASD** recognize JARDIANCE as the SGLT2 inhibitor with the strongest evidence of CV benefits5,6

---

**JARDIANCE**

(empagliflozin)

---

**NEW INDICATION Jardiance is now indicated in T2DM patients and established cardiovascular disease to reduce the risk of cardiovascular death**